Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Extrafine beclomethasone dipropionate breath-actuated inhaler (400 mu g/day) versus budesonide dry powder inhaler (800 mu g/day) in asthma
Autore:
Reichel, W; Dahl, R; Ringdal, N; Zetterstrom, O; Van Den Elshout, FJJ; Laitinen, LA;
Indirizzi:
Arhus Kommunehosp, Aarhus, Denmark Arhus Kommunehosp Aarhus DenmarkArhus Kommunehosp, Aarhus, Denmark Karolinska Hosp, Stockholm, Sweden Karolinska Hosp Stockholm SwedenKarolinska Hosp, Stockholm, Sweden Ziekenhuis Rijnstate, Arnhem, Netherlands Ziekenhuis Rijnstate Arnhem Netherlands Rijnstate, Arnhem, Netherlands Univ Helsinki, Cent Hosp, Helsinki, Finland Univ Helsinki Helsinki Finland v Helsinki, Cent Hosp, Helsinki, Finland
Titolo Testata:
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
fascicolo: 2, volume: 55, anno: 2001,
pagine: 100 - 106
SICI:
1368-5031(200103)55:2<100:EBDBI(>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
METERED-DOSE INHALER; MODERATE ASTHMA; HEALTHY-SUBJECTS; LUNG DEPOSITION; AEROSOL; SAFETY; MANAGEMENT; TURBUHALER; PROPELLANT; STEROIDS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Reichel, W Ludwigstr 21, D-61231 Bad Nauheim, Germany Ludwigstr 21 Bad Nauheim Germany D-61231 Bad Nauheim, Germany
Citazione:
W. Reichel et al., "Extrafine beclomethasone dipropionate breath-actuated inhaler (400 mu g/day) versus budesonide dry powder inhaler (800 mu g/day) in asthma", INT J CL PR, 55(2), 2001, pp. 100-106

Abstract

Hydrofluoroalkane-134a beclomethasone dipropionate extrafine aerosol breath-actuated inhaler (Qvar (TM) Autohaler (TM); BDP-AH) provides an alternative to chlorofluorocarbon metered dose inhalers or dry powder inhalers (DPIs), The aim of this six-week, open-label study was to determine whether BDP-AH demonstrates equivalent asthma control to twice the dose of budesonide (BUD)-DPI (Pulmicort Turbuhaler (R)), Adults with symptomatic asthma inadequately controlled on BUD-DPI 400 mug/day and beta -agonist were enrolled. Patients (n=193) were randomised to receive 400 mug/day BDP-AH (n=98) (two puffs of 100 mug/actuation inhaler twice daily) or 800 mug/day BUD-DPI (n=95)(two puffs of 200 mug/actuation inhaler twice daily). Both groups showed astatistically significant change from baseline in morning (a.m.) peak expiratory flow (PEF) at weeks 5-6 (p<0.01), indicating study treatment improved a.m, PEF over prestudy 400 <mu>g/day BUD. Changes from baseline in a.m. PEF at weeks 5-6 were 15.9 l/min for BDP-AH and 14.2 l/min for BUD-DPI; the groups were statistically equivalent (90% CI -7.02-10.44; p<-0.001 [equivalence=within <plus/minus> 25 l/min]). Other efficacy assessments (evening PEF, FEV1, asthma symptoms, P-agonist use) confirmed the treatments were clinically equivalent. Thirty-nine (40%) patients on BDP-AH and 35 (37%) on BUD-DPI experienced at least one adverse event (p=0.767). Four (4%) patients on BDP-AH and 3 (3%) on BUD-DPI reported increased asthma symptoms. BDP-AH at half the daily dose provided equivalent asthma control to BUD-DPI; both treatments were well tolerated.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:44:44